Becotatug vedotin shows 20.9% objective response in recurrent head and neck squamous cell carcinoma after prior therapy
For patients with advanced head and neck cancer, a new drug showed a 21% response rate in early testing
This multicenter, Phase IIa trial evaluated intravenous becotatug vedotin in 67 patients with recurrent or metastatic squamous cell carcinom…
A new drug shrank tumors in 21% of patients with advanced head and neck cancer who had run out of standard treatment options.
Phase 1b ABBV-368 combinations in recurrent/metastatic HNSCC show 14.3% overall response rate
Early study of ABBV-368 plus other drugs showed limited tumor response in head and neck cancer patients
This phase 1b, multicenter, open-label study enrolled 30 adults with recurrent or metastatic head and neck squamous cell carcinoma across th…
Early trials of ABBV-368 combined with other drugs showed limited tumor shrinkage in head and neck cancer patients despite a generally safe …
Low OT-NLR predicts superior survival in recurrent/metastatic HNSCC treated with cetuximab plus nivolumab
A Simple Blood Ratio May Predict Cancer Drug Success
This Phase II clinical trial evaluated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) receiving combine…
A low white blood cell ratio found in blood tests predicts better survival and treatment response for advanced head and neck cancer patients…
Phase 3 trial compares pembrolizumab with or without lenvatinib in PD-L1+ recurrent/metastatic HNSCC
Phase 3 trial tests pembrolizumab with or without lenvatinib for advanced head and neck cancer
A phase 3 randomized controlled trial enrolled 511 patients with PD-L1 selected recurrent or metastatic head and neck squamous cell carcinom…
A completed Phase 3 trial tested pembrolizumab with or without lenvatinib for advanced head and neck cancer, but detailed results are not ye…
Research across Head and Neck Cancer
Related studies from across the Head and Neck Cancer family.
Post-operative ctDNA linked to worse survival in HPV-negative HNSCC, but estimate unstable
ctDNA levels may signal cancer return in head and neck cancer
This meta-analysis examined post-operative ctDNA as a prognostic marker in HPV-negative head and neck squamous cell carcinoma. Detectable ct…
Detecting traces of cancer DNA in the blood after surgery may help identify patients at higher risk of cancer returning.
YAP and TAZ Overexpression Predicts Worse Survival in Oral Squamous Cell Carcinoma
Hippo Pathway Markers Linked to Oral Cancer Survival Rates
This meta-analysis of 17 studies examined the prognostic value of Hippo pathway effectors YAP and TAZ in oral squamous cell carcinoma. Poole…
New data suggests that specific proteins in the Hippo pathway may help predict survival outcomes for patients with oral squamous cell carcin…
Cisplatin Chemoradiotherapy for Elderly Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
New trial tests chemotherapy for elderly patients with head cancer
This trial protocol describes a study evaluating the use of weekly cisplatin in elderly patients with locally advanced squamous cell carcino…
A new trial aims to see if adding a specific chemotherapy drug helps elderly patients with advanced head and neck cancer.
EQ-5D Utility Values and Health Related Quality of Life
Understanding Quality of Life for Patients Living With Head and Neck Cancer
This meta-analysis quantifies EQ-5D utility scores for patients with head and neck cancer to inform survivorship care and cost-utility model…
New data helps doctors better understand how patients feel and function after being diagnosed with head and neck cancer.
Retropharyngeal lymph node involvement in oropharyngeal squamous cell carcinoma occurs in 11% to 16% of patients
Retropharyngeal lymph node involvement impacts staging for throat cancer
This meta-analysis of 8,887 patients with oropharyngeal squamous cell carcinoma (OPSCC) identified a pooled prevalence of retropharyngeal ly…
New data shows that certain lymph nodes in the throat area are more likely to spread cancer in specific types of throat cancer cases.
Response-adapted surgery after neoadjuvant immune checkpoint inhibitors improves pathologic complete response in mucosal HNSCC
Response-Adapted Surgery May Help Preserve Organs in Head Cancer
This meta-analysis of patients with resectable mucosal head and neck squamous cell carcinoma (HNSCC) found that response-adapted surgery (RA…
A new approach to surgery after immunotherapy may help patients with head and neck cancer keep more of their natural tissue and function.
HDAC inhibitors show 0.65 pooled favorable response rate in advanced head and neck cancer
HDAC Inhibitors Show Promise for Advanced Head and Neck Cancer
This meta-analysis of single-arm trials evaluated HDAC inhibitor therapy for advanced head and neck cancer. The analysis found a pooled cumu…
A review of clinical trials shows that HDAC inhibitors may help patients with advanced head and neck cancer when used in combination with ot…
Low tumor volume reduction on CT and high FDG-PET SUVmax correlate with poorer outcomes in head and neck cancer
Tumor Imaging Metrics May Predict Outcomes for Head and Neck Cancer
This meta-analysis of 98 studies evaluated in-treatment tumor response measurements for patients with head and neck cancer undergoing radiot…
Specific imaging markers like tumor volume on CT and SUVmax on PET scans may help predict how well head and neck cancer treatment progresses…
Smoking history linked to worse survival in HPV-positive oropharyngeal cancer after TORS
Smoking History Linked to Worse Survival in Throat Cancer
In HPV-associated oropharyngeal cancer treated with transoral robotic surgery, smoking history was tied to worse overall survival, though re…
A history of smoking is linked to a higher risk of death for patients with certain types of throat cancer treated with robotic surgery.
Oral HPV reshapes mucosal microbial composition in a sex and population dependent manner
Oral and genital health linked to specific bacteria and HPV
This mini-review synthesizes evidence regarding the interaction between HPV infection and mucosal microbiota in oral, anorectal, and penile …
New research shows how specific bacteria and the HPV virus interact in the mouth and genital areas to influence cancer risk.
Evaluating Dose Escalation to 60 Gy in Locally Advanced Esophageal Squamous Cell Carcinoma
Trial shows higher radiation dose does not improve cancer survival
A Phase 3 trial compares 60 Gy versus 50 Gy of radiotherapy with concurrent chemotherapy for patients with unresectable esophageal squamous …
A large trial shows that increasing radiation doses for advanced esophageal cancer does not improve survival but may increase side effects.
Weekly Cisplatin Regimen Shows Noninferiority to Standard Dosing in Head and Neck Cancer
Weekly cisplatin treatment shows promise for head and neck cancer
A randomized trial confirms that weekly cisplatin dosing achieves noninferiority in overall survival for high-risk squamous cell carcinoma p…
A new trial shows that giving chemotherapy weekly instead of every three weeks may offer a comparable survival rate for head and neck cancer…
Questions about Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
What is the objective response rate for becotatug vedotin in recurrent head and neck cancer?
Becotatug vedotin showed a 20.9% objective response rate in recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.
Full answer →